This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chambers, J. C. Articles by Kooner, J. S. Search for Related Content PubMed PubMed Citation Articles by Chambers, J. C. Articles by Kooner, J. S. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB (L)-METHIONINE Related Collections Endothelium/vascular type/nitric oxide Pathophysiology Risk Factors

(Arteriosclerosis, Thrombosis, and Vascular Biology. 1999;19:2922.)
© 1999 American Heart Association, Inc.

Atherosclerosis and Lipoproteins

Physiological Increments in Plasma Homocysteine Induce Vascular Endothelial Dysfunction in Normal Human Subjects

John C. Chambers; Omar A. Obeid; Jaspal S. Kooner

From the National Heart and Lung Institute, Imperial College School of Medicine, Hammersmith Hospital (J.C.C., J.S.K.), and DDRC, St Bartholomew’s and the Royal London School of Medicine & Dentistry, Queen Mary and Westfield College (O.A.O.), London, UK.

Correspondence to Dr J.S. Kooner, MD, FRCP, National Heart and Lung Institute, Imperial College School of Medicine, Hammersmith Hospital, Du Cane Rd, London W12 0NN, UK. E-mail j.kooner{at}ic.ac.uk

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Abstract—We hypothesized that physiological increments in plasma homocysteine after low-dose oral methionine or dietary animal protein induce vascular endothelial dysfunction and that there is a graded, inverse relationship between homocysteine concentration and endothelial function. We studied 18 healthy volunteers aged 18 to 59 years. Brachial artery flow-mediated and glyceryltrinitrate-induced dilatation were measured after 1) oral L-methionine (10, 25, and 100 mg/kg), 2) dietary animal protein (lean chicken 551±30 g, comprising 3.2±0.2 g methionine), and 3) methionine-free amino acid mix (100 mg/kg). Methionine (10, 25, and 100 mg/kg) induced a dose-related increase in homocysteine (9.4±1.3 to 12.2±2.1, 17.6±2.6, and 26.1±4.2 µmol/L, respectively; P<0.001) and a reduction in flow-mediated dilatation (4.1±0.8 to 2.1±0.8, 0.3±0.8, and -0.7±0.8%, respectively; P<0.001) at 4 hours. Compared with usual meal, animal protein increased plasma homocysteine (9.6±0.8 to 11.2±0.9 µmol/L, P=0.005) and reduced flow-mediated dilatation (4.5±0.7% to 0.9±0.6%, P=0.003). Methionine-free amino acid mix did not induce any changes. Glyceryltrinitrate-induced dilatation was unchanged throughout. In this study, small physiological increments in plasma homocysteine after low-dose methionine and dietary animal protein induced vascular endothelial dysfunction. We propose that protein intake–induced increments in plasma homocysteine may have deleterious effects on vascular function and contribute to the development and progression of atherosclerosis.

Key Words: homocysteine • endothelium • methionine • dietary protein

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Hyperhomocysteinemia is an independent risk factor for peripheral vascular,¹ cerebrovascular,² and coronary artery³ disease. Elevated homocysteine concentrations are found in almost one-third of all patients with atherosclerosis⁴ and levels only 12% above the upper limit of normal (15 µmol/L) are associated with a 3-fold increase in the risk of acute myocardial infarction.³

Homocysteine concentrations are determined by genetic and nutritional factors; mutations in the genes for enzymes involved in homocysteine metabolism, and deficiencies of vitamins B₆, B₁₂, and folic acid, are associated with hyperhomocysteinemia.⁵ Homocysteine is derived from the metabolism of the essential amino acid methionine. Methionine is found at greatest concentration in animal protein. In humans, dietary animal protein results in a transient rise in plasma homocysteine levels, which peaks at 8 hours and may persist for up to 24 hours.⁶ Previous studies have suggested animal protein intake may account for the day-to-day variation of up to 25% in plasma homocysteine.⁶

Increasing evidence suggests that the effects of elevated homocysteine are mediated through endothelial dysfunction. In children with cystathionine-ß-synthase deficiency and severe hyperhomocysteinemia⁷ and in adults with moderate hyperhomocysteinemia,^{8 9} chronically elevated homocysteine concentrations are associated with impaired endothelium-dependent vasodilatation. In primates, elevated homocysteine concentrations following a methionine-enriched diet for 4 weeks are associated with vascular endothelial dysfunction.¹⁰ Similarly, in normal human subjects, high-dose oral methionine (100 mg/kg), which increases plasma homocysteine by 3- to 4-fold, is accompanied by a reciprocal fall in brachial artery flow-mediated dilatation,^{11 12 13} an effect likely to be mediated through oxidative stress mechanisms.¹³

However, the major limitations of previous studies investigating the relationship between endothelial function and hyperhomocysteinaemia is that the homocysteine concentrations achieved have been at least 2- to 3-fold higher than normal.^{11 12 13} The vascular effects of physiological and diet-induced increments in plasma homocysteine have not been investigated previously. In this study, we have measured the effects of graded concentrations of homocysteine on brachial artery endothelium-dependent dilatation. To examine the physiological relevance of our findings, we have assessed vascular responses after dietary animal protein.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Eighteen healthy volunteers (11 male and 7 female), mean age 33 (range 18 to 59) years, were recruited from hospital staff. All were normotensive, with normal serum cholesterol, and with no previous history of diabetes or vascular disease. Six of the 18 subjects were active cigarette smokers, although their smoking pattern did not change during the course of the study. Smoking was not permitted on the study days. None were taking medications (including vitamin supplements or the oral contraceptive pill). All subjects gave informed and written consent. The study was approved by the local ethics committee.

Brachial artery flow-mediated dilatation (endothelium dependent) and glyceryltrinitrate-induced dilatation (glyceryltrinitrate [GTN], endothelium independent) were measured before and 4 hours after 1) oral L-methionine 10 mg/kg, 2) methionine 25 mg/kg, and 3) methionine 100 mg/kg. The measurements were extended to 8 and 24 hours during the high-dose methionine study. As a control, we performed studies after, 1) methionine-free amino-acid mix (100 mg/kg) and after, 2) diluted fruit juice alone (vehicle). To examine the physiological role of elevated homocysteine, we compared vascular responses after intake of lean chicken (551±30 g), comprising 3.2±0.2 g methionine, with changes after the usual meal. All studies were performed on separate days, in random order, and at least 14 days apart.

Brachial Artery Diameter
Studies were performed after an overnight fast with subjects supine and at rest. Room temperature ranged from 21°C to 24°C. Brachial artery flow-mediated dilatation was measured using a 7.0 MHz linear array transducer, an Acuson 128XP/10 system, and high resolution ultrasonic vessel wall tracking system (Vadirec), as described by Celermajer et al.¹⁴ The brachial artery was scanned longitudinally, and a stereotactic clamp used to hold the transducer in the same position throughout the procedure. The transmit (focus) zone was set to the depth of the near wall of the artery. Depth and gain settings were set to optimize images of the lumen-arterial wall interface. The images were magnified by a resolution box function and measurements taken from the anterior to posterior "m" line at end diastole, using the R-wave on the electrocardiogram. Brachial artery diameter was measured by identifying a clear section of the vessel on B-mode. The M-mode cursor was then placed over this point at right angles to the vessel wall. A 5 second segment of the A-Mode signal was then routed to the wall tracking system designed to track vessel wall movement on a beat-to-beat basis. The minimal arterial diameter was calculated from the distance between opposite lumen-arterial interfaces, as identified by manual selection of the maximal change in recorded radio frequency amplitude.

After the baseline resting scan, a pneumatic cuff placed at the level of the wrist was inflated to 300 mm Hg for 4.5 minutes. The second scan was performed 55 to 65 seconds after cuff deflation. Fifteen minutes were allowed for vessel recovery after which the second baseline scan was performed. GTN (400 mcg) was then administered and the fourth scan of the brachial artery undertaken. The vessel diameter was measured by 2 independent observers unaware of the subjects clinical details and the type and stage of the study. The technique for measurement of brachial artery flow-mediated dilatation is reproducible in our laboratory. There was a close correlation between the observers for brachial artery measurements (diameter 0.99, dilatation 0.90). The coefficient of variation for flow-mediated dilatation was 2%, based on measurements taken from the same subjects on separate days, under resting conditions. This compares favorably with other centers.¹⁵ Flow-mediated dilatation of conduit arteries is endothelium-dependent and largely mediated by nitric oxide.^{16 17}

Nutritional Products
Oral methionine was administered as L-methionine (Scientific Hospital Supplies) in diluted fruit juice (25 mg methionine per mL orange juice). Methionine-free amino acid mix (Scientific Hospital Supplies) was used as an amino acid control to exclude a nonspecific effect of amino acid ingestion on vascular responses. Methionine-free amino acid mix was administered in diluted fruit juice at the same concentration as L-methionine (methionine free mix comprises L-Alanine 0.04 g, L-Arginine 0.07 g, L-Aspartic acid 0.06 g, L-Carnitine 0.001 g, L-Cystine 0.03 g, L-Glutamic acid 0.07 g, L-Glutamine 0.01 g, Glycine 0.06 g, L-Histidine 0.04 g, L-Isoleucine 0.06 g, L-Leucine 0.10 g, L-Lysine 0.07 g, L-Phenylalanine 0.05 g, L-Proline 0.07 g, L-Serine 0.04 g, L-Threonine 0.05 g, L-Tryptophan 0.02 g, L-Tyrosine 0.05 g, L-Valine 0.07 g, and Taurine 0.001 g per g of mix).

Lean chicken was used as the dietary source of methionine. Subjects consumed 551±30 g chicken. This was chosen to provide a minimum of 2 g methionine per subject. The intake of chicken was timed as a single evening meal between 8 PM and 10 PM and vascular measurements performed 12 hours later to coincide with the expected time of peak homocysteine concentration.⁶ Chicken was purchased fresh as breast meat and grilled to cook. No dietary restrictions were applied for the usual meal. All recipes were recorded as weighed intakes and analyzed using the commercially available package Microdiet.

Biochemical Measurements
Fasting glucose, total cholesterol, high density lipoprotein (HDL) cholesterol, triglycerides, total plasma homocysteine, red-cell folate, and serum B₁₂ were measured for each subject. Samples for plasma homocysteine were collected before each vascular study. Additional samples for glucose and lipids were taken before and after the meal studies. Aliquots were placed on ice, centrifuged within 1 hour, and the separated plasma stored at -20°C before assays. Lipid profiles were determined using an Olympus AU800 multichannel analyzer; B12 and red cell folate by MEIA (Abbott IMX system) and total plasma homocysteine by high pressure-liquid chromatography. For each subject, samples were analyzed in 1 batch. The within assay coefficient of variation for homocysteine was 4%.

Data Processing and Statistical Analysis
Data were analyzed using Statistical Products and Service Solutions (SPSS) version 8.0 statistical package. Continuous data were expressed as mean±SEM. The effects of methionine 10, 25, and 100 mg/kg, compared with placebo on flow-mediated dilatation, GTN-induced dilatation, brachial artery diameter, and plasma homocysteine, were investigated by repeated measures ANOVA. When significant effects were identified, the paired samples t test was used post-hoc to localize differences, with Bonferonni’s adjustment for multiple comparisons. Measurements after animal protein meal were compared with those after usual meal, using the paired samples t test. For each study, the linear regression equations relating flow-mediated dilatation to plasma homocysteine were calculated for each subject and used to examine the presence of a relationship between flow-mediated dilatation and homocysteine in the study population. Statistical significance was inferred at a P value of <0.05.

	Results

Top Abstract Introduction Methods Results Discussion References

 
Clinical and Biochemical Characteristics
Baseline clinical and biochemical measurements are summarized in Table 1. All subjects were normotensive, with normal serum cholesterol, fasting blood glucose, red cell folate, and serum B₁₂. Baseline flow-mediated dilatation was 4.2±0.7% and was reproducible in individual subjects (coefficient of variation 2%). Flow-mediated dilatation was not significantly lower in smokers compared with nonsmokers (4.6±0.7% versus 4.1±1.1%, P=0.72).

View this table: [in this window] [in a new window]   Table 1. Baseline Clinical and Biochemical Measurements of Subjects

Effects of Oral Methionine
Oral methionine (100 mg/kg) induced a significant rise in plasma homocysteine at 2 hours (9.5±0.9 versus 26.1±4.2 µmol/L, P=0.001; Figure 1). The peak homocysteine response occurred at 8 hours (37.9±6.2 µmol/L), and levels returned towards normal, although were significantly higher than baseline, at 24 hours (19.6±5.1 µmol/L, P=0.05). After methionine, flow-mediated dilatation was impaired by 2 hours (4.2±0.7% to 1.8±1.1%, P=0.05). The maximal fall in flow-mediated dilatation occurred at 4 hours (0.1±0.9%, P=0.001), and responses returned towards normal at 24 hours. There was an inverse relationship between plasma homocysteine and flow-mediated dilatation (P=0.018). For each subject, a regression equation describing their relationship between flow-mediated dilatation and plasma homocysteine was generated. The fitted model predicting mean flow-mediated dilatation for the study population was described by the following equation: flow-mediated dilatation=5.05-(0.14xplasma homocysteine), where the standard error of the intercept=0.99, and the standard error of the regression slope=0.05. There were no changes in GTN-induced, endothelium-independent dilatation (20.0±1.8% to 18.6±1.4%, P=0.41) before and after methionine. Baseline brachial artery diameter (4.1±0.2 to 4.1±0.2 mm, P=0.37), basal brachial arterial flow (103±15 to 111±15 mL/min, P=0.32), and the hyperemic increase in brachial arterial flow (138±19% to 143±19%, P=0.86) were also unchanged before and after methionine.

View larger version (13K): [in this window] [in a new window]   Figure 1. Plasma homocysteine concentrations and flow-mediated dilatation during a 24-hour period after oral methionine 100 mg/kg (mean±SEM, n=15). *P<0.05, **P<0.01 compared with responses at 0 hours.

Compared with baseline, methionine at doses of 10 mg/kg and 25 mg/kg increased plasma homocysteine (9.4±1.3 to 12.2±2.1 µmol/L, P=0.007 and 9.6±1.4 to 17.6±2.6 µmol/L, P<0.001, respectively) and reduced flow-mediated dilatation (4.1±0.8% to 2.1±0.8%, P=0.05 and 3.6±0.9% to 0.3±0.8%, P=0.008, respectively; Figure 2). Similar to after high-dose methionine study, vascular function was related to plasma homocysteine in the low-dose methionine studies. Flow-mediated dilatation was impaired after methionine in the 11 subjects in whom the increments in plasma homocysteine did not exceed the upper limit of normal (15 µmol/L, homocysteine 7.6±0.9 to 9.7±0.6 µmol/L, P<0.001; flow-mediated dilatation 5.3+1.1 to 1.9+0.8, P=0.04).

View larger version (14K): [in this window] [in a new window]   Figure 2. Plasma homocysteine concentrations and flow-mediated dilatation (mean±SEM, n=17) 4 hours after fruit juice alone (vehicle) and after methionine 10, 25, 100 mg/kg. *P<0.05, **P<0.01 compared with responses after fruit juice alone.

Effects of Methionine-Free Amino Acid Mix and Fruit Juice Alone
After methionine-free amino acid mix or following fruit juice alone (vehicle), there were no changes in plasma homocysteine (9.8±1.6 to 9.9±1.7 µmol/L, P=0.81 and 9.4+0.8 to 10.0±1.0 µmol/L, P=0.18, respectively) or flow-mediated dilatation (3.3+0.9% to 4.4±0.7%, P=0.34 and 4.4+1.1% to 4.4±1.0%, P=0.98, respectively), excluding a nonspecific effect of amino acids or fruit juice on the observed vascular changes.

Effects of Usual Meal and Intake of Animal Protein
Compared with usual meal, intake of animal protein, comprising 3.2±0.2 g methionine, was associated with an increase in plasma homocysteine (from 9.6±0.8 to 11.2±0.9 µmol/L, P=0.005; Figure 3) and fall in flow-mediated dilatation (4.5±0.7% to 0.9±0.6%, P=0.003; Figure 4). Flow-mediated dilatation was related to plasma homocysteine (P=0.05). Intake of animal protein was not accompanied by any significant change in total, LDI or HDL cholesterol, or triglycerides, although blood glucose was lower compared with usual meal (Table 2). Univariate analysis did not show any relationship between flow-mediated dilatation and blood glucose. Animal protein did not affect GTN induced dilatation, baseline brachial arterial diameter, basal brachial arterial blood flow, or the hyperemic increase in brachial artery blood flow (Table 2).

View larger version (18K): [in this window] [in a new window]   Figure 3. Plasma homocysteine 1) before and 4 hours after low-dose methionine 10 mg/kg (n=14) and 2) 12 hours after usual meal and animal protein meal (n=17).

View larger version (19K): [in this window] [in a new window]   Figure 4. Flow-mediated dilatation 1) before and 4 hours after low-dose methionine 10 mg/kg (n=14) and 2) 12 hours after usual meal and animal protein meal (n=17).

View this table: [in this window] [in a new window]   Table 2. Homocysteine Concentrations and Brachial Artery Vascular Responses 12 Hours After Usual Meal and Animal Protein Meal

Nutritional analysis of meals confirmed that intake of total protein and methionine was higher in animal protein compared with usual meal (Table 2). Intakes of total energy and fat were similar and carbohydrate lower in animal protein than usual meal.

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
We have shown that physiological increments of 2 to 3 µmol/L in plasma homocysteine after low-dose oral methionine and dietary animal protein induce vascular endothelial dysfunction. In this study, we observed an inverse and dynamic relationship between plasma homocysteine and endothelial function.

We found evidence of impaired flow-mediated dilatation within 2 hours of high dose oral methionine (100 mg/kg), the dietary precursor of homocysteine. Regression analysis showed an inverse relationship between homocysteine concentration and flow-mediated dilatation. Previous studies show that brachial artery flow-mediated dilatation is endothelium dependent¹⁶ and is largely mediated by the release of nitric oxide.¹⁷ Our findings therefore imply that vascular endothelial nitric oxide activity may be impaired during acutely elevated homocysteine concentrations. Previous studies have shown that high dose methionine, which elevates plasma homocysteine concentrations to more than 2- to 3-fold normal, is associated with endothelial dysfunction.^{11 12 13} However, in these studies, concentrations of plasma homocysteine have exceeded those encountered in the majority of patients with premature vascular disease.^{3 18 19 20} The vascular effects of physiological increments in plasma homocysteine have not been investigated previously. In this study, we administered methionine at lower doses to examine the effects of small increments in plasma homocysteine on the vascular endothelium. In our subjects, methionine 25 mg/kg resulted in an 8 µmol/L increment and methionine 10 mg/kg resulted in a 2.8 µmol/L increment in plasma homocysteine. These levels of plasma homocysteine were accompanied by a rapid and dose-related impairment of brachial artery endothelium-dependent dilatation. Our observations lend support to the hypothesis that the vascular effects of homocysteine are graded^{3 18 19 20} as in the case of cholesterol and present even during small increments in plasma homocysteine.

To examine the physiological relevance of our observations, we studied the vascular effects of animal protein, the major dietary source of methionine. Mean homocysteine concentration rose by 1.6 µmol/L after animal protein and was accompanied by a reduction in endothelium-dependent dilatation, compared with responses after the usual meal. These are the first data to provide evidence of a deleterious effect of dietary animal protein on vascular endothelial function. Previous studies have suggested a relationship between animal protein intake and atherosclerosis^{21 22 23 24} and proposed a role for disturbances in lipid metabolism.²⁵ In this study, endothelial dysfunction induced by animal protein was not accompanied by changes in blood lipids. Instead, our data support a key role for homocysteine in the mechanisms underlying the association between dietary animal protein and endothelial dysfunction. Metabolic studies in humans show that high animal protein intake may affect homocysteine levels for at least 8 hours and may contribute to intraindividual day-to-day variation in fasting homocysteine of up to 25%.⁶ Based on the results of the present study, physiological changes in homocysteine of this magnitude may impair vascular endothelial function, and in susceptible subjects, contribute to the development and progression of atherosclerosis and thrombosis.

Our results do not exclude a direct effect of methionine on endothelial function, although previous studies that have examined the vascular effects of high dose oral methionine have not shown a convincing relationship between plasma methionine concentrations and flow-mediated dilatation.¹² In our subjects, impaired endothelium-dependent dilatation after methionine was not due to a nonspecific effect of amino acid ingestion because there was no change in flow-mediated dilatation after the methionine-free amino acid mix. Both methionine and methionine-free preparations were isocaloric, isotonic, and isovolaemic, which suggests that factors such as fluid balance shifts or gastric emptying were unlikely to have influenced endothelium-dependent dilatation. In the present study, methionine (100 mg/kg) induced a maximal rise in plasma homocysteine at 8 hours and fall in flow-mediated dilatation at 4 hours. Precise reasons for the recovery in flow-mediated dilatation despite rising plasma homocysteine concentrations are not clear but may include the formation and release of protective vasodilator substances such as S-nitrosothiols and S-nitrosohomocysteine, substances with potent vasodilator and platelet inhibitor properties.²⁶ However, a different study design will be necessary to determine the separate effects of methionine, homocysteine, and related species.

In summary, our results show that vascular endothelial dysfunction can be induced by small increments in plasma homocysteine after low dose oral methionine. Similar disturbances in endothelial function are also evident after physiological increments in plasma homocysteine (2 to 3 µmol/L) after dietary animal protein. Protein intake–related increments in plasma homocysteine may therefore have deleterious effects on vascular function and contribute to the development and progression of atherosclerosis in man.

	Acknowledgments

 
We are indebted to Caroline Doré for statistical advice, Louise Boustead for the dietary analyses, and Andrew McGregor and Jeff Jean-Marie for their assistance in the vascular studies.

Received January 28, 1999; accepted July 8, 1999.

	References

Top Abstract Introduction Methods Results Discussion References

 

1. Boers GH, Smals AG, Trijbels FJ, Fowler B, Bakkeren JA, Schoonderwaldt HC, Kleiger WJ, Kloppenborg PW. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med. 1985;313:709–715.[Abstract]
2. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet. 1995;346:1395–1398.[Medline] [Order article via Infotrieve]
3. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997;337:230–236.[Abstract/Free Full Text]
4. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991;324:1149–1155.[Abstract]
5. McCully KS. Homocysteine and vascular disease. Nat Med. 1996;2:386–389.[Medline] [Order article via Infotrieve]
6. Guttormsen AB, Schneede J, Fiskerstrand T, Ueland PM, Refsum HM. Plasma concentrations of homocysteine and other aminothiol compounds are related to food intake in healthy human subjects. J Nutr. 1994;124:1934–1941.
7. Celermajer DS, Sorensen K, Ryalls M, Robinson J, Thomas O, Leonard JV, Deanfield JE. Impaired endothelial function occurs in the systemic arteries of children with homozygous homocystinuria but not in their heterozygous parents. J Am Coll Cardiol. 1993;22:854–858.[Abstract]
8. Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation. 1997;95:1119–1121.[Abstract/Free Full Text]
9. Woo KS, Chook P, Lolin YI, Cheung AS, Chan LT, Sun YY, Sanderson JE, Metreweli C, Celermajer DS. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation. 1997;96:2542–2544.[Abstract/Free Full Text]
10. Lentz SR, Sobey CG, Piegors DJ, Bhopatkar MY, Faraci FM, Malinow MR, Heistad DD. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Invest. 1996;98:24–29.[Medline] [Order article via Infotrieve]
11. Chambers JC, McGregor A, Jean Marie J-, Kooner JS. Acute hyperhomocysteinaemia and endothelial dysfunction. Lancet. 1998;351:36–37.[Medline] [Order article via Infotrieve]
12. Bellamy MF, McDowell IFW, Ramsey MW, Brownlee M, Bones C, Newcombe RG, Lewis MJ. Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in healthy adults. Circulation. 1998;98:1848–1852.[Abstract/Free Full Text]
13. Chambers JC, McGregor A, Jean-Marie J, Obeid OA, Kooner JS. Demonstration of rapid onset vascular endothelial dysfunction following hyperhomocysteinaemia: an effect reversible with vitamin C therapy. Circulation. 1999;99:1156–1160.[Abstract/Free Full Text]
14. Celermajer DS, Adams MR, Clarkson P, Robinson J, McCreadie R, Donald A, Deanfield JE. Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults. N Engl J Med. 1996;334:150–154.[Abstract/Free Full Text]
15. Leeson P, Thorne S, Donald A, Mullen M, Clarkson P, Deanfield J. Non-invasive measurement of endothelial function: effect on brachial artery dilation of graded endothelial dependent and independent stimuli. Heart. 1997;78:22–27.[Abstract/Free Full Text]
16. Pohl U, Holtz J, Busse R, Bassenge E. Crucial role of endothelium in the vasodilator response to increased flow in vivo. Hypertension. 1986;8:37–44.[Abstract/Free Full Text]
17. Joannides R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thuillez C, Luscher TF. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation. 1995;91:1314–1319.[Abstract/Free Full Text]
18. Selhub J, Jacques PF, Bostom AG, D’Agostino RB, Wilson PW, Belanger AJ, O’Leary DH, Wolf PA, Schaefer EJ, Rosenberg IH. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med. 1995;332:286–291.[Abstract/Free Full Text]
19. Malinow MR, Nieto FJ, Szklo M, Chambless LE, Bond G. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The Atherosclerosis Risk in Communities Study. Circulation. 1993;87:1107–1113.[Abstract/Free Full Text]
20. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA. 1995;274:1049–1057.[Abstract]
21. Richardson M, Kurowska EM, Carroll KK. Early lesion development in the aortas of rabbits fed low-fat, cholesterol-free, semipurified casein diet. Atherosclerosis. 1994;107:165–178.[Medline] [Order article via Infotrieve]
22. Moore MC, Guzman MA, Schilling PE, Strong JP. Dietary-atherosclerosis study on deceased persons: relation of selected dietary components to raised coronary lesions. J Am Diet Assoc. 1976;68:216–223.[Medline] [Order article via Infotrieve]
23. Fau D, Peret J, Hadjiisky P. Effects of ingestion of high protein or excess methionine diets by rats for two years. J Nutr. 1988;118:128–133.
24. Carroll KK. Hypercholesterolemia and atherosclerosis: effects of dietary protein. Fed Proc. 1982;41:2792–2796.[Medline] [Order article via Infotrieve]
25. Carroll KK, Kurowska EM. Soy consumption and cholesterol reduction: review of animal and human studies. J Nutr. 1995;125:594S–597S.
26. Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D, Loscalzo J. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest. 1993;91:308–318.

This article has been cited by other articles:

				F. Mariotti, J. F. Huneau, I. Szezepanski, K. J. Petzke, Y. Aggoun, D. Tome, and D. Bonnet Meal Amino Acids with Varied Levels of Arginine do Not Affect Postprandial Vascular Endothelial Function in Healthy Young Men J. Nutr., June 1, 2007; 137(6): 1383 - 1389. [Abstract] [Full Text] [PDF]

				C. Antoniades, D. Tousoulis, K. Marinou, C. Vasiliadou, C. Tentolouris, G. Bouras, C. Pitsavos, and C. Stefanadis Asymmetrical dimethylarginine regulates endothelial function in methionine-induced but not in chronic homocystinemia in humans: effect of oxidative stress and proinflammatory cytokines. Am. J. Clinical Nutrition, October 1, 2006; 84(4): 781 - 788. [Abstract] [Full Text] [PDF]

				S R Hart, A A Mangoni, C G Swift, and S H D Jackson Effect of methionine loading on pulse wave analysis in elderly volunteers. Postgrad. Med. J., August 1, 2006; 82(970): 524 - 527. [Abstract] [Full Text] [PDF]

				P. J. Garlick Toxicity of Methionine in Humans J. Nutr., June 1, 2006; 136(6): 1722S - 1725S. [Abstract] [Full Text] [PDF]

				P. Verhoef, T. van Vliet, M. R Olthof, and M. B Katan A high-protein diet increases postprandial but not fasting plasma total homocysteine concentrations: a dietary controlled, crossover trial in healthy volunteers Am. J. Clinical Nutrition, September 1, 2005; 82(3): 553 - 558. [Abstract] [Full Text] [PDF]

				J. T. Kielstein, S. M. Bode-Boger, G. Hesse, J. Martens-Lobenhoffer, A. Takacs, D. Fliser, and M. M. Hoeper Asymmetrical Dimethylarginine in Idiopathic Pulmonary Arterial Hypertension Arterioscler. Thromb. Vasc. Biol., July 1, 2005; 25(7): 1414 - 1418. [Abstract] [Full Text] [PDF]

				M. L. Bots, J. Westerink, T. J. Rabelink, and E. J.P. de Koning Assessment of flow-mediated vasodilatation (FMD) of the brachial artery: effects of technical aspects of the FMD measurement on the FMD response Eur. Heart J., February 2, 2005; 26(4): 363 - 368. [Abstract] [Full Text] [PDF]

				L. E. Mignini, P. M. Latthe, J. Villar, M. D. Kilby, G. Carroli, and K. S. Khan Mapping the Theories of Preeclampsia: The Role of Homocysteine Obstet. Gynecol., February 1, 2005; 105(2): 411 - 425. [Abstract] [Full Text] [PDF]

				B. Smolkova, M. Dusinska, K. Raslova, M. Barancokova, A. Kazimirova, A. Horska, V. Spustova, and A. Collins Folate levels determine effect of antioxidant supplementation on micronuclei in subjects with cardiovascular risk Mutagenesis, November 1, 2004; 19(6): 469 - 476. [Abstract] [Full Text] [PDF]

				P. Verhoef, G. R Steenge, E. Boelsma, T. van Vliet, M. R Olthof, and M. B Katan Dietary serine and cystine attenuate the homocysteine-raising effect of dietary methionine: a randomized crossover trial in humans Am. J. Clinical Nutrition, September 1, 2004; 80(3): 674 - 679. [Abstract] [Full Text] [PDF]

				T. Suhara, K. Fukuo, O. Yasuda, M. Tsubakimoto, Y. Takemura, H. Kawamoto, T. Yokoi, M. Mogi, T. Kaimoto, and T. Ogihara Homocysteine Enhances Endothelial Apoptosis via Upregulation of Fas-Mediated Pathways Hypertension, June 1, 2004; 43(6): 1208 - 1213. [Abstract] [Full Text] [PDF]

				A. Vychytil, M. Fodinger, J. Pleiner, M. Mullner, P. Konner, S. Skoupy, C. Rohrer, M. Wolzt, and G. Sunder-Plassmann Acute effect of amino acid peritoneal dialysis solution on vascular function Am. J. Clinical Nutrition, November 1, 2003; 78(5): 1039 - 1045. [Abstract] [Full Text] [PDF]

				F. Wotherspoon, D. W Laight, K. M Shaw, and M. H Cummings Review: Homocysteine, endothelial dysfunction and oxidative stress in type 1 diabetes mellitus The British Journal of Diabetes & Vascular Disease, September 1, 2003; 3(5): 334 - 340. [Abstract] [PDF]

				M. C. Stuhlinger, R. K. Oka, E. E. Graf, I. Schmolzer, B. M. Upson, O. Kapoor, A. Szuba, M. R. Malinow, T. C. Wascher, O. Pachinger, et al. Endothelial Dysfunction Induced by Hyperhomocyst(e)inemia: Role of Asymmetric Dimethylarginine Circulation, August 26, 2003; 108(8): 933 - 938. [Abstract] [Full Text] [PDF]

				A. De Bree, W. M. M. Verschuren, D. Kromhout, L. A. J. Kluijtmans, and H. J. Blom Homocysteine Determinants and the Evidence to What Extent Homocysteine Determines the Risk of Coronary Heart Disease Pharmacol. Rev., December 1, 2002; 54(4): 599 - 618. [Abstract] [Full Text] [PDF]

				O. Stanger, H.-J. Semmelrock, W. Wonisch, U. Bos, E. Pabst, and T. C. Wascher Effects of Folate Treatment and Homocysteine Lowering on Resistance Vessel Reactivity in Atherosclerotic Subjects J. Pharmacol. Exp. Ther., October 1, 2002; 303(1): 158 - 162. [Abstract] [Full Text] [PDF]

				N. Weiss, C. Keller, U. Hoffmann, and J. Loscalzo Endothelial dysfunction and atherothrombosis in mild hyperhomocysteinemia Vascular Medicine, August 1, 2002; 7(3): 227 - 239. [Abstract] [PDF]

				E.M. Cottington, C. LaMantia, S. P. Stabler, R. H. Allen, A. Tangerman, C. Wagner, S. H. Zeisel, and S. H. Mudd Adverse Event Associated With Methionine Loading Test: A Case Report Arterioscler. Thromb. Vasc. Biol., June 1, 2002; 22(6): 1046 - 1050. [Abstract] [Full Text] [PDF]

				M. D. Silverman, R. J. Tumuluri, M. Davis, G. Lopez, J. T. Rosenbaum, and P. I. Lelkes Homocysteine Upregulates Vascular Cell Adhesion Molecule-1 Expression in Cultured Human Aortic Endothelial Cells and Enhances Monocyte Adhesion Arterioscler. Thromb. Vasc. Biol., April 1, 2002; 22(4): 587 - 592. [Abstract] [Full Text] [PDF]

				M.C. Verhaar, E. Stroes, and T.J. Rabelink Folates and Cardiovascular Disease Arterioscler. Thromb. Vasc. Biol., January 1, 2002; 22(1): 6 - 13. [Abstract] [Full Text] [PDF]

				N. Weiss, Y.-Y. Zhang, S. Heydrick, C. Bierl, and J. Loscalzo Overexpression of cellular glutathione peroxidase rescues homocyst(e)ine-induced endothelial dysfunction PNAS, October 12, 2001; (2001) 231428998. [Abstract] [Full Text] [PDF]

				J. C CHAMBERS and J. S KOONER Homocysteine: a novel risk factor for coronary heart disease in UK Indian Asians Heart, August 1, 2001; 86(2): 121 - 122. [Full Text] [PDF]

				J.C. Chambers and J.S. Kooner Homocysteine -- an innocent bystander in vascular disease? Eur. Heart J., May 1, 2001; 22(9): 717 - 719. [PDF]

				A. A Brown and F. B Hu Dietary modulation of endothelial function: implications for cardiovascular disease Am. J. Clinical Nutrition, April 1, 2001; 73(4): 673 - 686. [Abstract] [Full Text] [PDF]

				G. Sesmilo, B. M. K. Biller, J. Llevadot, D. Hayden, G. Hanson, N. Rifai, and A. Klibanski Effects of Growth Hormone (GH) Administration on Homocyst(e)ine Levels in Men with GH Deficiency: A Randomized Controlled Trial J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1518 - 1524. [Abstract] [Full Text]

				E. Nurk, G. S. Tell, O. Nygård, H. Refsum, P. M. Ueland, and S. E. Vollset Plasma Total Homocysteine Is Influenced by Prandial Status in Humans: The Hordaland Homocysteine Study J. Nutr., April 1, 2001; 131(4): 1214 - 1216. [Abstract] [Full Text]

				Z. Bagi, Z. Ungvari, L. Szollar, and A. Koller Flow-Induced Constriction in Arterioles of Hyperhomocysteinemic Rats Is Due to Impaired Nitric Oxide and Enhanced Thromboxane A2 Mediation Arterioscler. Thromb. Vasc. Biol., February 1, 2001; 21(2): 233 - 237. [Abstract] [Full Text] [PDF]

J. C. Chambers, P. M. Ueland, O. A. Obeid, J. Wrigley, H.